A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

Inclusion Criteria: * At least age of 18 years at screening. * Patients of advanced solid tumor，who have progressed on or intolerant to standard therapy. * With measurable lesion according to RECIST 1.1. * Agree to provide fresh or archival tumor tissue. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1. Exclusion Criteria: * Previous or current treatment with KRAS G12D inhibitors. * Uncontrolled pleural, ascites or pericardial effusion. * Known and untreated, or active central nervous system metastases. * History of other primary malignant tumors. * Serious, uncontrolled, or active comorbidities. * Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications.